(Q46888030)

English

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients

scientific article published on 14 November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

1 reference

based on heuristic

inferred from title

author name string

V Michaud

1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

M-C Vanier

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

D Brouillette

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

D Roy

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

L Verret

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

N Noel

6

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

I Taillon

7

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

G O'Hara

8

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

D Gossard

9

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

M Champagne

10

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

K Goodman

11

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

Y Renaud

12

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

A Brown

13

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

M Phillips

14

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

A M Ajami

15

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

J Turgeon

16

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

language of work or name

0 references

publication date

14 November 2007

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

83

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

740-748

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

21 January 2018

A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacogenetics of warfarin elimination and its clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of warfarin enantiomers: A search for intrasubject correlations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting the maintenance dose of warfarin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of pharmacogenetics to guide warfarin therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Human P450 metabolism of warfarin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100434

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.CLPT.6100434

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/18030307

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46888030&oldid=2136265892"